Information technology facilitates cost-effectiveness analysis in developing countries an observational study of breast cancer chemotherapy in Taiwan

PharmacoEconomics

Volumn 27, Issue 11, 2009, Pages 947-961

  Shih, Ya Chen Tina ^a   Pan, I Wen ^a   Tsai, Yi Wen ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

AGE; ARTICLE; BAYES THEOREM; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; COMORBIDITY; COST EFFECTIVENESS ANALYSIS; DEVELOPING COUNTRY; DRUG DOSE REGIMEN; FEMALE; GEOGRAPHY; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; INFORMATION TECHNOLOGY; MASTECTOMY; MEDICAL INFORMATION; MONOTHERAPY; NATIONAL HEALTH INSURANCE; OBSERVATIONAL STUDY; PARTIAL MASTECTOMY; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY ANALYSIS; TAIWAN; TEACHING HOSPITAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BAYES THEOREM; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; CYCLOPHOSPHAMIDE; CYTARABINE; DEVELOPING COUNTRIES; ECONOMICS, PHARMACEUTICAL; EPIRUBICIN; FEMALE; FLUOROURACIL; HEALTH CARE COSTS; HUMANS; INFORMATION SYSTEMS; INSURANCE CLAIM REPORTING; METHOTREXATE; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; POLICY MAKING; TAIWAN;

EID: 70449369356     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11314110-000000000-00000     Document Type: Article

References (31)

1. WHO. The world health report 2000: health systems. Improving performance. Geneva: WHO, 2000 [online]. Available at URL: http://www.who.int/whr/2000/en/ index. html [Accessed 2008 Sep. 10]
2. Kumar S, Russell RR. Technology change, technological catch-up, and capital deepening: relative contributions to growth and convergence. Am Econ Rev 2002; 92(3):527-48
3. Rogers M. The international diffusion of technology: technological catch-up and economic growth. In: Bloch H, Kenyon P, editors. Creating an internationally competitive economy. New York: Palgrave MacMillan, 2001: 207-32
4. Chang SC, Chen YC, Hu OY. Antibiotic use in public hospitals in Taiwan after the implementation of National Health Insurance. J Formos Med Assoc 2001; 100(3):155-61
5. McDonald LC, Yu HT, Yin HC, et al. Correlates of antibiotic use in Taiwan hospitals. Infect Control Hosp Epidemiol 2001; 22(9):565-71
6. Chang HJ, Huang N, Lee CH, et al. The impact of the SARS epidemic on the utilization of medical services: SARS and the fear of SARS. Am J Public Health 2004; 94(4):562-4
7. Saltman RB, Figueras J. Analyzing the evidence on European health care reforms. Health Aff (Millwood) 1998; 17(2):85-108
8. Buxton MJ. Economic evaluation and decision making in the UK. Pharmacoeconomics 2006; 24(11):1133-42
9. Laupacis A. Economic evaluations in the Canadian common drug review. Pharmacoeconomics 2006; 24(11):1157-62
10. Cheng TM. Taiwan's new national health insurance program: genesis and experience so far. Health Aff (Millwood) 2003; 22(3):61-76
11. Bureau of National Health Insurance (BNHI). 2008 National Health Insurance briefing 2008 [online]. Available from URL: http://www.nhi.gov. tw/english/index.asp [Accessed 2008 Sep. 15]
12. Bureau of National Health Insurance (BNHI). Building an online environment: promotion of e-medical care services. 2006 [online]. Available from URL: http://www.nhi.gov. tw/webdata/webdata.asp?menu=1&menu-id= &webdata-ID=1940 [Accessed 2008 Sep. 20]
13. Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40 (8 Suppl.) : IV-3-18
14. Nattinger AB, Laud PW, Bajorunaite R, et al. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res 2004; 39 (6 Pt 1) : 1733-49
15. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Health Econ 2002; 11(5):415-30
16. Shih YC, Bekele NB, Xu Y. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients. Pharmacoeconomics 2007; 25(10):843-62
17. Spiegelhalter DJ, Thomas A, Best NG. WinBUGS version 1.2 user manual. Cambridge: MRC Biostatistics Unit, 1999
18. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53(12):1258-67
19. Gelman A, Carlin JB, Stern HS, et al. Bayesian data analysis. New York: Chapman & Hall, 1998
20. Norum J, Holtmon M. Adjuvant fluorouracil, epirubicin and cyclophosphamide in early breast cancer: is it costeffective? Acta Oncol 2005; 44(7):735-41
21. Fryback DG, Stout NK, Rosenberg MA. An elementary introduction to Bayesian computing using WinBUGS. Int J Technol Assess Health Care 2001; 17(1):98-113
22. International Monetary Fund (IMF). World economic outlook database, 2005 Apr. [online]. Available from URL: http://www.internationalmonetaryfund.com/ external/pubs /ft/weo/2005/01/data/dbginim.cfm [Accessed 2008 Sep. 18]
23. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365(9472):1687-717
24. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998; 16(8):2651-8
25. Piccart MJ, Di Leo A, Beauduin M, et al. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001; 19(12):3103-10
26. Trudeau ME. Optimizing adjuvant breast cancer chemotherapy: rationale for the MA 21 study. Oncology (Williston Park) 2001; 15 (5 Suppl. 7) : 7-13
27. Anders CK, Hsu DS, Broadwater G, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008; 26(20):3324-30
28. El Saghir NS, Seoud M, Khalil MK, et al. Effects of young age atpresentation on survival in breast cancer. BMC Cancer 2006; 6: 194 [online]. Available from URL: http://www.biomedcentral.com/1471-2407/6/194 [Accessed 2009 Sep. 6]
29. Pfeiffer P, Cold S, Rose C. Cytotoxic treatment of metastatic breast cancer: which drugs and drug combinations to use? Acta Oncol 1992; 31(2):219-24
30. Mouridsen HT, Alfthan C, Bastholt L, et al. Current status of epirubicin (farmorubicin) in the treatment of solid tumours. Acta Oncol 1990; 29(3):257-85
31. Trudeau M, Charbonneau F, Gelmon K, et al. Selection of adjuvant chemotherapy for treatment of node-positive breast cancer. Lancet Oncol 2005; 6(11):886-98